![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Here's an interesting new biotechnology stock. Recently spun off from Collagen, the stock has been dying on the vine, so to speak. Insiders, however, have been piling into the stock, which sells for ~1/2 book. The company recently received permission to sell its CoStasis Surgical Hemostat in Europe. The product is also in late stage trials in the U.S. Anyone interested should take a look at the company's recent press releases, which pretty well spell out the story.
| ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |